Rare Dysfunctional
AAMD, advanced age-related macular degeneration
AMD, age-related macular degeneration
AREDS, Age-Related Eye Disease Study
Advanced age-related macular degeneration
BMI, body mass index
C3, complementcomponent 3
C9, complementcomponent 9
CD35, cluster of differentiation 35 (also called complement receptor 1)
CD46, cluster of differentiation 46 (also called membrane cofactor protein)
CFH, complementfactor H
CFI, complement factor I
CI, confidence interval
COOH, carboxy terminal
CR1, complement receptor 1
Complement factor I
FI, factor I protein
GA, geographic atrophy
GRS, genetic risk score
Genetic variants
Geographic atrophy
HR, hazard ratio
NH2, amino terminal
NV, neovascular
Neovascular disease
OR, odds ratio
SAS, Statistical Analysis System
SLCS, Seddon Longitudinal Cohort Study
Journal
Ophthalmology science
ISSN: 2666-9145
Titre abrégé: Ophthalmol Sci
Pays: Netherlands
ID NLM: 9918230896206676
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
01
08
2022
revised:
02
12
2022
accepted:
27
12
2022
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
To evaluate associations between rare dysfunctional Prospective, longitudinal study. Patients aged 55 to 80 years at baseline identifying as White with non-AAMD in 1 or both eyes at baseline were included. Follow-up grades were assigned as early, intermediate, or AAMD (GA or NV). Analyses were performed using the Seddon Longitudinal Cohort Study (N = 2116 subjects, 3901 eyes, and mean follow-up of 8.3 years) and the Age-Related Eye Disease Study (N = 2837 subjects, 5200 eyes, and mean follow-up of 9.2 years). Progression to AAMD, GA, or NV. In the prospective cohort of 4953 subjects (9101 eyes with non-AAMD at baseline), 1% were type 1 rare Results suggest that carriers of rare dysfunctional type 1 Proprietary or commercial disclosure may be found after the references.
Identifiants
pubmed: 36909148
doi: 10.1016/j.xops.2022.100265
pii: S2666-9145(22)00154-3
pmc: PMC9993025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100265Subventions
Organisme : NEI NIH HHS
ID : R01 EY022445
Pays : United States
Informations de copyright
© 2022 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology.
Références
Trans Am Ophthalmol Soc. 2005;103:173-84; discussion 184-6
pubmed: 17057801
PLoS One. 2014 Jan 31;9(1):e87047
pubmed: 24498017
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7395-400
pubmed: 20385826
Hum Mol Genet. 2015 Jul 1;24(13):3861-70
pubmed: 25788521
Invest Ophthalmol Vis Sci. 2009 May;50(5):2044-53
pubmed: 19117936
Annu Rev Pathol. 2017 Jan 24;12:25-52
pubmed: 27959629
Arch Ophthalmol. 2001 Oct;119(10):1417-36
pubmed: 11594942
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):18
pubmed: 32516404
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Biochem J. 1987 Mar 15;242(3):849-56
pubmed: 2954545
Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6513-6528
pubmed: 29288272
Hum Mol Genet. 2021 Jun 17;30(13):1188-1199
pubmed: 33783477
Nat Genet. 2013 Nov;45(11):1366-70
pubmed: 24036952
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6873-8
pubmed: 26501415
JAMA Ophthalmol. 2015 Jul;133(7):785-91
pubmed: 25880396
Nephrol Dial Transplant. 2011 Oct;26(10):3159-65
pubmed: 21339308
Nat Genet. 2011 Oct 23;43(12):1232-6
pubmed: 22019782
Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):32
pubmed: 33369641
Am J Ophthalmol. 2019 Feb;198:223-261
pubmed: 30389371
Sci Rep. 2016 Aug 30;6:31531
pubmed: 27572114
Eur J Hum Genet. 2009 Jan;17(1):100-4
pubmed: 18685559
Am J Ophthalmol. 1999 Jul;128(1):45-53
pubmed: 10482093
Hum Mol Genet. 2022 Oct 28;31(21):3683-3693
pubmed: 35531992
Transl Vis Sci Technol. 2020 Aug 24;9(9):37
pubmed: 32908800
Ophthalmology. 2006 Feb;113(2):260-6
pubmed: 16458093
Hum Mol Genet. 2014 Oct 1;23(19):5283-93
pubmed: 24847005
Mol Immunol. 2014 Oct;61(2):118-125
pubmed: 25034031
Am J Ophthalmol. 2011 Feb;151(2):345-52.e3
pubmed: 21122828
Nat Genet. 2007 Oct;39(10):1200-1
pubmed: 17767156
Kidney Int Rep. 2019 Apr 09;4(7):1007-1017
pubmed: 31312772